Genetic studies suggest that changes affecting GIP signaling may increase breast cancer risk, indicating that GLP-1 and GIP pathways could influence cancer development
The endocrinologist or prescribing physician manages the indication for treatment, dose escalation, metabolic response, systemic side effects and long-term safety
Share the piece
However, due to (i) rareness of the disease (unfamiliar to most neurologists), (ii) non-inclusion of GNE genetic testing for neurological indications, and (iii) non-specific symptoms at disease onset (foot-drop, balance impairment), the diagnosis of these patients is difficult and often delayed
Compounding and the FDA: Questions and Answers, Peptide Compounding Guidance Update 2024
Using the Wrong Syringe Conversion Not all syringes measure the same way